This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
November 29, 2012 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that it won the Licensing Deal of the Year Award at the Scrip Awards 2012 event held in
London last night. The Company received the global industry recognition for its partnership agreement with Alcon (Novartis) to commercialize JETREA
® (ocriplasmin) outside the U.S. JETREA
® is the first pharmacological treatment for vitreomacular adhesion (VMA), a progressive sight-threatening disease. JETREA
® was recently approved by the U.S. Food and Drugs Administration for the treatment of symptomatic Vitreomacular Adhesion (VMA). The JETREA
® European Marketing Authorisation Application is currently under review by the European Medicines Agency. A decision on European approval is expected in the first half of 2013.
The Scrip Awards, now in their eighth year, are one of the most prestigious awards recognizing excellence in the global biopharmaceutical and clinical research industries. The awards are judged by an independent panel of senior executives from these sectors against strict criteria.
The Licensing Deal of the Year reflects the major partnership alliance that ThromboGenics and Alcon signed for the commercialization of JETREA
Europe and Rest of the World (ROW). In the US, ThromboGenics will commercialize the drug by itself.
Upon the signing of the deal in
March 2012, ThromboGenics received an upfront payment of €75 million. ThromboGenics is eligible to receive up to a further €300 million in potential milestone payments. ThromboGenics could also receive an attractive level of royalties based on the net sales of JETREA
® in the ROW, which would give it a significant share of the product's economics outside the U.S. In addition, ThromboGenics and Alcon have agreed to work together and share the costs of developing new clinical applications or presentations of JETREA
Patrik De Haes, CEO of ThromboGenics, said: "Winning this prestigious industry award is a clear recognition of the strategic importance of this licensing deal for both ThromboGenics and Alcon. As a result of this agreement, we now have the best possible partner to commercialize JETREA
® outside the U.S. With JETREA
®, Alcon has gained access to a novel pharmacological treatment option that could lead to paradigm shift in the treatment of symptomatic vitreomacular adhesion."
® (ocriplasmin) is a truncated form of human plasmin for the treatment of symptomatic VMA. JETREA
® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and
Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
®'s Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA
® was generally well tolerated with most adverse events being transient and mild in severity.